Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.73 |
| ▸ | AURKA | O14965 | 3/20 | 0.73 |
| ▸ | BRD4 | O60885 | 4/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.63 |
| ▸ | EGFR | P00533 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCND2 | P30279 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355852 | 0.90 | FGFR4 (0.63) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1353760 | 0.90 | EGFR (0.65) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1356819 | 0.90 | CDK4 (0.59) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1353747 | 0.88 | AURKA (0.58) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1355147 | 0.88 | TBK1 (0.61) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL3585855 | 0.87 | CDK4 (0.59) | CDK4AURKAFGFR4EGFRKDR | |
| SCHEMBL344015 | 0.87 | CDK4 (0.66) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1355810 | 0.86 | CDK4 (0.60) | CDK4AURKABRD4FGFR4EGFR | |
| SCHEMBL1355529 | 0.84 | EIF2AK4 (0.53) | CDK4AURKABRD4EGFRSRC | |
| SCHEMBL1356097 | 0.81 | MAPT (0.52) | CDK4AURKAKDRLCKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK4 101/4885AURKA 9/4885BRD4 1688/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | CDK4 101/4885AURKA 9/4885BRD4 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.